Appendix 1: Various drugs Seattle Genetics has had in its pipeline over time

Mouse over any drug to see more details about the drug.

Initiated Drug Target Indication Status
2001 mAb SGN-70 CD70 Cancer Ongoing
2001 mAb Vorsetuzumab mafodotin (SGN-75) CD70 Renal cell cancer and NHL Discontinued 2014
2001 SGN-10 Lewis-Y (CD174) Cancer Discontinued 2002
2002 ADC Vandortuzumab vedotin (RG7450, DSTP3086S) STEAP1 Prostate cancer Discontinued 2017
2002 ADC (DMOT/ RG7600) mesothelin Pancreatic, ovarian cancer Ongoing
2002 ADC (RG7841/DLYE5953A) Ly6E Breast, non-small cell lung cancer Ongoing
2002 ADC Lifastuzumab vedotin (RG7599, DNIB0600A) NaPi2b Ovarian cancer, non-small cell lung cancer Ongoing
2002 ADC Polatuzumab vedotin (RG7596, DCDS4501A) CD79b Non-Hodgkin lymphoma Ongoing
2002 ADC RG7636 (DEDN-6526A, DEDN6526A) ETBR Melanoma Ongoing
2002 ADC SGN-15 Lewis-Y Breast, colon, prostrate, ovarian and non-small cell lung cancer Discontinued 2005
2002 ADC Sofituzumab vedotin (RG7458) MUC16 Ovarian cancer Discontinued 2015
2002 ADEPT therapy SGN-17/19 Melanoma Ongoing
2002 mAb Dacetuzumab (SGN-40, SGN14) CD40 NHL, multiple myeloma Discontinued 2009
2002 mAb SGN-30 CD30 ALCL, HL, ALCL Discontinued 2006
2002 Pinatuzumab vedotin RG7593 CD22 Non-hodgkin Lymphoma Ongoing
2002 RG7882 MUC16 Ovarian, pancreatic cancer Discontinued 2018
2002 RG7986 Non-Hodgkin lymphoma Ongoing
2002 Undisclosed ADCs Cancer Ongoing
2004 ADC C4.4a Solid tumors Ongoing
2004 ADC CA9 Solid tumors Ongoing
2004 ADC FGFR2 Cancer Ongoing
2004 ADC Glembatumumab vedotin GPNMB Breast cancer, Melanoma Ongoing
2005 ADC PSMA Prostate cancer Ongoing
2005 mAb Lintuzumab (SGN-33) CD33 AML and myelodysplastic syndromes Discontinued 2010
2007 ADC AGS-16 Renal cell cancer Ongoing
2007 ADC CD37 Cancer Ongoing
2007 ADC AGS-16C3F ENPP3 Renal cell cancer Ongoing
2007 ADC ASG5ME AGS-5 Pancreatic, prostrate, gastric cancer Discontinued 2013
2007 ADC Denitnuzumab mafodotin (SGN-CD19A, SGN-19A) CD19 DLBCL, follicular lymphoma Discontinued 2018
2007 ADC Enfortumab vedotin/PADCEV (ASG22ME) Nectin-4 Metastatic urothelial cancer, non-small cell lung, head and neck, gastric/esophageal and breast cancers Approved 2019
2007 ADC Sirtratumab vedotin (ASG-15ME) SLTRK6 Bladder cancer Ongoing
2008 Undisclosed ADC Cancer Ongoing
2009 ADC BCMA Multiple myeloma, hematologic malignancies Ongoing
2009 ADC AGS-16 Renal cell cancer Ongoing
2009 ADC Brentuximab vendotin/Adcetris (SGN-35) CD30 Relapsed or refactory HL and sALCL Approved 2011
2009 ADC Indusatumab Vedotin TAK-264 (MLN0264) GCC (guanylyl cyclase C) Panreatic cancer Discontinued 2016
2010 3 undisclosed ADCs Cancer Ongoing
2010 ADC EGFR Squamous cell tumors, glioblastoma Ongoing
2010 ADC 5T4-MMAF 5T4 Solid tumors Ongoing
2011 ADC AXL Solid tumors Ongoing
2011 ADC CD74 Hematologic malignancies, solid tumors Ongoing
2011 ADC SGN48A CD48A Relapsed or Refractory Myeloma Ongoing
2011 ADC Tisotumab vedotin Tissue factor Solid tumors, Cervical cancer Ongoing
2011 Undisclosed ADCs Cancer Ongoing
2012 ADC Ladiratuzumab vedotin (SGN-LIV1A) LIV-1 Breast cancer Ongoing
2012 ADC Vadastuximab talirine (CD33A) CD33 AML Discontinued 2017
2015 T cell therapy ACTR087 SEA-BCMA Multiple myeloma Ongoing
2016 2-fluorofucose SGN-2FF Advanced solid tumours Ongoing
2016 ADC (SGN-CD123A) CD123 AML Discontinued 2018
2018 Tucatinib HER2 Breast cancer Ongoing

2001

mAb SGN-70

2001

mAb Vorsetuzumab mafodotin (SGN-75)

2001

SGN-10

2002

ADC Vandortuzumab vedotin (RG7450, DSTP3086S)

2002

ADC (DMOT/ RG7600)

2002

ADC (RG7841/DLYE5953A)

2002

ADC Lifastuzumab vedotin (RG7599, DNIB0600A)

2002

ADC Polatuzumab vedotin (RG7596, DCDS4501A)

2002

ADC RG7636 (DEDN-6526A, DEDN6526A)

2002

ADC SGN-15

2002

ADC Sofituzumab vedotin (RG7458)

2002

ADEPT therapy SGN-17/19

2002

mAb Dacetuzumab (SGN-40, SGN14)

2002

mAb SGN-30

2002

Pinatuzumab vedotin RG7593

2002

RG7882

2002

RG7986

2002

Undisclosed ADCs

2004

ADC

2004

ADC

2004

ADC

2004

ADC Glembatumumab vedotin

2005

ADC

2005

mAb Lintuzumab (SGN-33)

2007

ADC

2007

ADC

2007

ADC AGS-16C3F

2007

ADC ASG5ME

2007

ADC Denitnuzumab mafodotin (SGN-CD19A, SGN-19A)

2007

ADC Enfortumab vedotin/PADCEV (ASG22ME)

2007

ADC Sirtratumab vedotin (ASG-15ME)

2008

Undisclosed ADC

2009

ADC

2009

ADC

2009

ADC Brentuximab vendotin/Adcetris (SGN-35)

2009

ADC Indusatumab Vedotin TAK-264 (MLN0264)

2010

3 undisclosed ADCs

2010

ADC

2010

ADC 5T4-MMAF

2011

ADC

2011

ADC

2011

ADC SGN48A

2011

ADC Tisotumab vedotin

2011

Undisclosed ADCs

2012

ADC Ladiratuzumab vedotin (SGN-LIV1A)

2012

ADC Vadastuximab talirine (CD33A)

2015

T cell therapy ACTR087

2016

2-fluorofucose SGN-2FF

2016

ADC (SGN-CD123A)

2018

Tucatinib

Approved Discontinued Ongoing

Source: Seattle Genetic's Annual Reports.

Respond to or comment on this page on our feeds on Facebook, Instagram or Twitter.